Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

Authors: Philip Home, Stuart Pocock, Henning Beck‐Nielsen, Paula Curtis, Ramón Gomis, M Hanefeld, Nigel C. Jones, Michel Komajda, John J.V. McMurray - The Lancet 2009 cited by 1,397